Samsung Bioepis v. Regeneron Pharmaceuticals
Unfair Competition PI Case
Dismissal decision
Meeting your
business goals
together
We stand by always ready to provide
optimal strategies for your company
scroll
Topics
& News
open_in_new
ABE & PARTNERS represented Regeneron Pharmaceuticals against Samsung Bioepis in an Unfair Competition PI Case and received a dismissal decision.
open_in_new
ABE & PARTNERS represented Bayer Healthcare against Samsung Bioepis in an Unfair Competition PI Case and received a dismissal decision.
open_in_new
NEW
ABE & PARTNERS wins Boutique Law Firm of the Year at ALB Japan Law Awards 2025.
open_in_new
NEW
ABE & PARTNERS was selected as BRONZE by IAM Patent 1000 2025 in the category of Litigation.
Cases
Samsung Bioepis v. Bayer Healthcare
Unfair Competition PI Case
Dismissal decision
X v. U.S. Pharmaceutical Company
Patent Opposition
Patent maintained
Japanese Pharmaceutical Company v. Indian Pharmaceutical Company
Trial for Patent Invalidation for vaccine patent
Invalidity decision
Baxalta v. Chugai
Patent Infringement Lawsuit regarding bispecific antibody
Publications
"Trailblazing Innovation: Takanori Abe's Visionary Leadership in Intellectual Property Law"
Source : Industry Chronicle
"ABE & PARTNERS: The Architects of Legal Innovation in a Borderless World"
Source : BIZTECH OUTLOOK
"A True Pioneer in Intellectual Property Law: Mr. Takanori ABE’s Empowering Journey"
Source : PRIME VIEW
"Five minutes with…Takanori Abe, Abe & Partners"
Source : Managing Intellectual Property
"[GUEST POST] Antitrust defense to patent infringement in Japan: IP High Court overruled Tokyo District Court in toner cartridge recycling case"
Source : FOSS PATENTS
“International IP
Law Firm of the Year”― ACQ Global Awards
Information
-
＜Caution＞
ABE & PARTNERS has received information that the name of our firm and atrorney from our office have been used to attempt to commit fraud.
If you receive any contact from an unknown person using the name of our office or an attorney from our office, do not respond immediately, but please fully confirm the identity of that person.
In addition, we would greatly appreciate your informing us by using "Contact".